202 related articles for article (PubMed ID: 14719804)
41. Cis-Configured aziridines are new pseudo-irreversible dual-mode inhibitors of Candida albicans secreted aspartic protease 2.
Degel B; Staib P; Rohrer S; Scheiber J; Martina E; Büchold C; Baumann K; Morschhäuser J; Schirmeister T
ChemMedChem; 2008 Feb; 3(2):302-15. PubMed ID: 18038380
[TBL] [Abstract][Full Text] [Related]
42. Legumain forms from plants and animals differ in their specificity.
Rotari VI; Dando PM; Barrett AJ
Biol Chem; 2001 Jun; 382(6):953-9. PubMed ID: 11501761
[TBL] [Abstract][Full Text] [Related]
43. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
44. Two novel asparaginyl endopeptidase-like cysteine proteinases from the protist Trichomonas vaginalis: their evolutionary relationship within the clan CD cysteine proteinases.
León-Félix J; Ortega-López J; Orozco-Solís R; Arroyo R
Gene; 2004 Jun; 335():25-35. PubMed ID: 15194187
[TBL] [Abstract][Full Text] [Related]
45. Solid-phase methods for the preparation of epoxysuccinate-based inhibitors of cysteine proteases.
Sadaghiani AM; Verhelst SH; Bogyo M
J Comb Chem; 2006; 8(6):802-4. PubMed ID: 17096566
[No Abstract] [Full Text] [Related]
46. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.
Matsumoto K; Mizoue K; Kitamura K; Tse WC; Huber CP; Ishida T
Biopolymers; 1999; 51(1):99-107. PubMed ID: 10380357
[TBL] [Abstract][Full Text] [Related]
47. Interaction of papain-like cysteine proteases with dipeptide-derived nitriles.
Löser R; Schilling K; Dimmig E; Gütschow M
J Med Chem; 2005 Dec; 48(24):7688-707. PubMed ID: 16302809
[TBL] [Abstract][Full Text] [Related]
48. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors.
Meara JP; Rich DH
J Med Chem; 1996 Aug; 39(17):3357-66. PubMed ID: 8765519
[TBL] [Abstract][Full Text] [Related]
49. Proteinases participating in the processing and activation of prolegumain in primary cultured rat macrophages.
Lecaille F; Muno D; Kominami E; Ishidoh K
Biol Chem; 2004 Jun; 385(6):511-6. PubMed ID: 15255183
[TBL] [Abstract][Full Text] [Related]
50. Rational design of improved aziridine-based inhibitors of cysteine proteases.
Buback V; Mladenovic M; Engels B; Schirmeister T
J Phys Chem B; 2009 Apr; 113(15):5282-9. PubMed ID: 19301885
[TBL] [Abstract][Full Text] [Related]
51. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
52. Optimization of peptidyl allyl sulfones as clan CA cysteine protease inhibitors.
Fennell BD; Warren JM; Chung KK; Main HL; Arend AB; Tochowicz A; Götz MG
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):468-78. PubMed ID: 22380780
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and evaluation of chloromethyl sulfoxides as a new class of selective irreversible cysteine protease inhibitors.
Brouwer AJ; Bunschoten A; Liskamp RM
Bioorg Med Chem; 2007 Nov; 15(22):6985-93. PubMed ID: 17869119
[TBL] [Abstract][Full Text] [Related]
54. Syntheses and SH-enzyme inhibitory activities of new epoxysuccinic acid piperazine derivatives against mu-calpain and cathepsin B.
Inoue J; Yoshida Y; Nakamura M; Cui YS; Nagao Y
Drug Des Discov; 1999 Aug; 16(2):165-9. PubMed ID: 10533812
[TBL] [Abstract][Full Text] [Related]
55. Atomistic insights into the inhibition of cysteine proteases: first QM/MM calculations clarifying the regiospecificity and the inhibition potency of epoxide- and aziridine-based inhibitors.
Mladenovic M; Junold K; Fink RF; Thiel W; Schirmeister T; Engels B
J Phys Chem B; 2008 May; 112(17):5458-69. PubMed ID: 18393547
[TBL] [Abstract][Full Text] [Related]
56. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase.
Loak K; Li DN; Manoury B; Billson J; Morton F; Hewitt E; Watts C
Biol Chem; 2003 Aug; 384(8):1239-46. PubMed ID: 12974392
[TBL] [Abstract][Full Text] [Related]
57. Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.
Furet P; Imbach P; Noorani M; Koeppler J; Laumen K; Lang M; Guagnano V; Fuerst P; Roesel J; Zimmermann J; García-Echeverría C
J Med Chem; 2004 Sep; 47(20):4810-3. PubMed ID: 15369383
[TBL] [Abstract][Full Text] [Related]
58. Identification of a cDNA encoding an active asparaginyl endopeptidase of Schistosoma mansoni and its expression in Pichia pastoris.
Caffrey CR; Mathieu MA; Gaffney AM; Salter JP; Sajid M; Lucas KD; Franklin C; Bogyo M; McKerrow JH
FEBS Lett; 2000 Jan; 466(2-3):244-8. PubMed ID: 10682836
[TBL] [Abstract][Full Text] [Related]
59. The synthesis and utilization of 2,4-dinitrophenyl-labeled irreversible peptidyl diazomethyl ketone inhibitors.
Hawthorne SJ; Pagano M; Harriott P; Halton DW; Walker B
Anal Biochem; 1998 Aug; 261(2):131-8. PubMed ID: 9716415
[TBL] [Abstract][Full Text] [Related]
60. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents.
Micale N; Kozikowski AP; Ettari R; Grasso S; Zappalà M; Jeong JJ; Kumar A; Hanspal M; Chishti AH
J Med Chem; 2006 Jun; 49(11):3064-7. PubMed ID: 16722625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
